Here’s a snippet from Brugger’s presentation this morning:
“There’s been some speculation as to how the FDA’s action on generic Lovenox applies to generic Copaxone… What I like is the fact that FDA has shown it can work with applicants with high science and come up with a totality argument to tackle these complex-mixture drugs and make them generic. I think that very much plays into our favor for generic Copaxone.”
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.